Key result
Platelet VEGF levels before IVIG treatment were significantly correlated with the maximum coronary artery abnormalities z-score (r = 0.524, P = 0.02) in patients with Kawasaki syndrome.
Why the study?
Are platelet VEGF levels associated with IVIG treatment response and coronary artery abnormalities in patients with Kawasaki syndrome?
Observational (n=80)
Are platelet VEGF levels associated with IVIG treatment response and coronary artery abnormalities in patients with Kawasaki syndrome?
Effect estimate: r = 0.524
p-value: p=0.02
Platelet VEGF levels may serve as a useful biomarker for predicting the severity of vasculitis and the development of coronary artery abnormalities in Kawasaki syndrome.
Platelet VEGF may flag higher coronary risk in Kawasaki syndrome; leaves open its clinical utility and requires prospective validation.
Kawasaki syndrome (KS) is an acute febrile vasculitis of childhood. Coronary artery abnormalities (CAA) are a significant problem in KS patients. High dose intravenous immunoglobulin (IVIG) is effective for reducing the occurrence of CAA. Clinical and histopathological findings suggest that vascular endothelial growth factor (VEGF) is involved in CAA. In circulating blood, newly activated platelets are the major source of VEGF, which is released in large amounts in vascular inflammation. The present study analysed 80 KS patients (69 IVIG responders and 11 IVIG non-responders) and evaluated the role of platelet VEGF in KS vasculitis. Serum VEGF and platelet VEGF levels were significantly higher in KS patients than controls (P < 0.001). Platelet VEGF reflected the reactivity of IVIG treatment and was decreased in responders (P < 0.001), but remained increased in non-responders (P = 0.01). Platelet VEGF levels, but not serum VEGF levels, before IVIG were significantly correlated with the maximum CAA z-score (r = 0.524, P = 0.02). Our findings demonstrate that platelet VEGF may reflect the severity of vasculitis related to the pathological development of CAA in KS. Platelet VEGF may be an important feature of KS pathophysiology.
No takes yet. Share an insight, caveat, or question.
Ueno et al. (2009) conducted an observational in Kawasaki syndrome (n=80). Platelet VEGF levels vs. Controls was evaluated on Correlation with maximum coronary artery abnormalities (CAA) z-score (r = 0.524, p=0.02). Platelet VEGF levels before IVIG treatment were significantly correlated with the maximum coronary artery abnormalities z-score (r = 0.524, P = 0.02) in patients with Kawasaki syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: